The information learned in these studies will help to inform doctors as to how to appropriately adjust doses of cannabidiol and tacrolimus in order to improve health outcomes and long-term treatment success for transplant recipients.
- Study Type: Interventional
- Study Design
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Supportive Care
- Masking: None (Open Label)
- Study Primary Completion Date: September 2027
The commercial availability of cannabidiol, or CBD oil, has increased in the United Stated and this supplement has the potential to cause a variety of drug-drug interactions, including in solid organ transplant recipients who receive tacrolimus to prevent rejection. Through a series of pharmacokinetic and pharmacodynamics assays, this proposal will identify gene-drug and drug-drug interactions (DDI), including those that place transplant recipients at risk for increased toxicity related to their immunosuppression. The information learned in these studies will help to inform practitioners as to whether cannabidiol needs to be avoided in transplant recipients and how to appropriately adjust doses of CBD and immunosuppression in order to improve health outcomes and long-term treatment success in this high-risk population.
- Drug: Tacrolimus single dose
- 5 mg once
- Drug: Epidiolex single dose
- Epidiolex 5 mg/kg
- Drug: Epidiolex steady-state and tacrolimus single dose
- Epidiolex at up to 5 mg/kg twice daily (for 14 days) and tacrolimus 5 mg once on day 12 of period
Arms, Groups and Cohorts
- Active Comparator: CYP3A5 expressers without chronic kidney disease
- Active Comparator: CYP3A5 non-expressers without chronic kidney disease
- Active Comparator: CYP3A5 expressers with chronic kidney disease
- Active Comparator: CYP3A5 non-expressers with chronic kidney disease
Clinical Trial Outcome Measures
- Primary Outcome Measures
- Time Frame: 27 days
- The primary outcome is the AUC0-Infinity ratio of tacrolimus with cannabidiol divided by tacrolimus alone between CYP3A5 expressers and non-expressers in subjects with and without chronic kidney disease (CKD). Subjects with and without CKD will be analyzed separately.
- Secondary Outcome Measures
- Time Frame: 27 days
- Immune cell distribution and signaling as measured by scRNA sequencing. The hypothesis tested is that cannabidiol will induce T regulatory lymphocytes (Tregs) and reduce overall cytokine signaling as compared to tacrolimus alone. Period 1 and Period 3 will be compared.
Participating in This Clinical Trial
- Age 18-65 – Are judged healthy enough to participate as determined by and decided from a pre-enrollment screening session that includes medical history and laboratory tests such as blood and urine tests, and electrocardiography (EKG). – Agree to refrain from taking any prescription medications, over-the-counter medications, and herbal, dietary, and alternative supplements that may interact with the metabolism of the study drugs at least 2 weeks prior to the start of the study and until study completion. – Are willing to commit the time requested for this study – Are willing to refrain from smoking or use of tobacco or marijuana for at least two weeks prior to and until the completion of the study (the entire study lasts for approximately 26 days). Additional Criteria for the Healthy volunteer study: • Have a GFR above 60 ml/min/1.73m2 with proteinuria less than 0.3 grams by urine protein to creatinine ratio or 24 hour urine collection Additional Criteria for the CKD study: – Have either: – A GFR between 16 ml/min and 60 ml/min/1.73m2 or – The presence of greater than 0.3 grams of proteinuria by urine protein to creatinine ratio or 24 hour urine collection, but less than 3.5 gm of nephrotic range proteinuria as hypoalbuminemia may impact protein binding. Exclusion Criteria:
- Unable to provide informed consent – Have history of intolerance, allergic reactions (e.g. rash) or other forms of hypersensitivities to any of the study medications (tacrolimus or cannabidiol); – Are currently taking sedative agents, including agents for insomnia – Are underweight (body mass index (BMI) less than 18.5) or overweight [body mass index (BMI) greater than 35] – Have a positive pregnancy serum or urine test obtained just prior to each study, or are breast feeding – Are night shift workers – Have an eGFR < 15 ml/min/1.73m2 or are on dialysis. – Have compromised liver function as defined by pre-screening bilirubin, AST and ALT testing including any elevation of bilirubin or AST/ALT more than 2x the upper limit of normal. – Have a positive urine drug screen for Cannabis or Marijuana in the last 3 months. – Have a Hgb < 10.0 g/dL – Have gastrointestinal (digestive) disorders such as persistent diarrhea or malabsorption that would interfere with the absorption of orally administered drugs – Have a history of or current seizure disorder – Are currently on immunosuppression or are immunosuppressed. – Are recipients of a current allograft (heart, kidney, pancreas, liver, intestine, lung, stem cell transplant). – Have baseline EKG readings that are abnormal that could place the patient at the high risk. – Have alcohol (more than 4 alcoholic drinks per day on a regular basis) or drug abuse, including opioids, or have used tobacco products or marijuana within the past three months, and are unwilling or unable to stop taking these medications two weeks prior to and during the entire study period – Have participated in a research study involving intensive blood sampling or have donated blood within the past two months – Had an unplanned hospitalization in the last 6 months or two or more unplanned hospitalizations in the last 2 years. – Are taking prescription medications, that may interfere with the metabolism of the study drugs (e.g., inhibitors or inducers of CYP3A4/5 or CYP2C19 or those that will displace protein binding of tacrolimus/cannabidiol). Interactions will be screened according to the Flockhart table. – Are taking over-the-counter medications, herbal or dietary supplements, and alternative medicines that may interfere with the metabolism of the study drugs (e.g., inhibitors or inducers of CYP3A4/5 or CYP2C19 or those that will displace protein binding of tacrolimus/cannabidiol) that the subject is unwilling or unable to stop over the course of the study. Interactions will be screened according to the Flockhart table. – Are students under supervision of any of the study investigators. – Cannot commit the time requested for this study. – Have a known CYP3A4 *22/*22 genotype
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 65 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
- Lead Sponsor
- Indiana University
- Provider of Information About this Clinical Study
- Principal Investigator: Michael Eadon, Associate Professor of Medicine – Indiana University School of Medicine
- Overall Official(s)
- Michael Eadon, MD, Principal Investigator, Indiana University School of Medicine
- Zeruesenay Desta, PhD, Principal Investigator, Indiana University School of Medicine
- Overall Contact(s)
- Michael Eadon, MD, (317) 274-2502, email@example.com
Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, Wang D, Vinks AA, He Y, Swen JJ, Leeder JS, van Schaik R, Thummel KE, Klein TE, Caudle KE, MacPhee IA. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther. 2015 Jul;98(1):19-24. doi: 10.1002/cpt.113. Epub 2015 Jun 3.
Brown JD, Winterstein AG. Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. J Clin Med. 2019 Jul 8;8(7). pii: E989. doi: 10.3390/jcm8070989. Review.
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.